| Autor: |
Timsit, José, Chanson, Philippe, Larger, Etienne, Duet, Michèle, Mosse, Arlette, Guillausseau, Pierre Jean, Harris, Alan G., Moulonguet, Michel, Warnet, André, Lubetzki, Jean |
| Zdroj: |
European Journal of Endocrinology; September 1987, Vol. 116 Issue: 1 p108-112, 5p |
| Abstrakt: |
Abstract. Multiple scinjections of a long-acting somatostatin analogue (SMS 201-995) are currently used in the treatment of acromegaly. However, plasma GH concentration often reaches a pathological level (> 5 μg/l) between two injections. In seven patients with active acromegaly we compared, in a short-term trial, the effect of SMS 201-995 administered by continuous scinfusion (50 μg and 100 μg a day) and by three scinjections (100 μg each). In six patients, plasma GH levels were significantly reduced regardless of the mode and dose of treatment (P< 0.05). However, comparing diurnal profiles, 100 μg continuous scinfusion was more effective than discontinuous administration in reducing the number of GH levels above 5 μg/l (P< 0.01). In two patients, continuous infusion was the only way to decrease all plasma GH values below 5 μg/l during the diurnal profile determination. Moreover, even when, in a long-term study, the dose of multiple injections was progressively increased to 500 μg three times a day, GH levels remained consistently elevated in one of these patients. Thus, in some acromegalic patients continuous scinjection seems currently the most efficient way of treatment with SMS 201-995. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
